Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab).
- The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab).
- The Company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept.
- In the bevacizumab-naïve population (n=179), the median PFS in the batiraxcept plus paclitaxel arm was 5.4 months, compared to 5.4 months in the paclitaxel arm.
- In the overall population, the median PFS in the batiraxcept plus paclitaxel arm was 5.1 months, compared to 5.5 months in the paclitaxel arm.